Hodgkin lymphoma

The lymphatic system — nodes, vessels, spleen, thymus and marrow — is the immune system’s infrastructure, and lymphomas are its cancers. Hodgkin lymphoma — historically called Hodgkin disease — is the variant Thomas Hodgkin first described in 1832, distinguished from the far larger non-Hodgkin family by a peculiarity: the malignant Reed-Sternberg cells, giant B-lymphocytes gone wrong, typically make up only a small minority of a swollen node’s bulk, sitting in an inflammatory crowd they themselves recruit. That biology explains several of the disease’s signatures — the systemic “B symptoms” driven by the cytokine noise, the orderly node-to-node spread along lymphatic chains that made staging and radiotherapy historically effective, and, in the modern era, an unusual vulnerability to immune checkpoint drugs.

Classical Hodgkin lymphoma accounts for the great majority of cases and divides into four histological subtypes — nodular sclerosis (the commonest, typical of young adults with chest disease), mixed cellularity, lymphocyte-rich and lymphocyte-depleted — which colour presentation more than they change treatment today. A fifth entity, nodular lymphocyte-predominant Hodgkin lymphoma, is biologically distinct, indolent, and managed on its own rules; a diagnosis letter naming it is describing a different, gentler disease.

The epidemiology is distinctive: incidence peaks in young adulthood with a second rise in later life; the Epstein-Barr virus is found within tumour cells in a sizeable minority of cases (association, not destiny — most EBV-infected people never develop lymphoma); and immunosuppression, including HIV, raises risk. Overall it is an uncommon cancer with an outsized presence in survival statistics, because so many of its patients are young and cured — which is also why late effects of treatment, decades on, have shaped the modern instinct to treat no harder than necessary.

Where care happens shapes little in early disease — the protocols are standardised and travel well — and more at relapse, where transplant experience, PET quality and trial access separate centres. The disease’s young demographic adds its own logistics: education interrupted mid-course, careers paused, fertility clinics booked against chemotherapy calendars, parents and partners drafted into care roles. Units that treat many young adults have built the scaffolding — fertility fast-tracks, psychology, work and study letters — and it is legitimate to weigh that scaffolding when choosing where to be treated.

The classic presentation is a lymph node — most often in the neck or just above the collarbone — that is enlarged, rubbery, mobile and painless, persisting and slowly growing over weeks. Painless is the operative word and the reason for delay: without the ache of infection, a young person waits. Nodes in the armpit or groin, or several regions at once, tell the same story. A large share of young adults harbour disease in the mediastinum — the node-rich space behind the breastbone — which may be silent, or may declare itself with dry cough, chest fullness, breathlessness on lying flat, or, uncommonly, swelling of the face and neck veins when great-vessel compression develops (an urgent-review picture).

The systemic voice of the disease is the “B symptom” triad that staging formally counts: drenching night sweats (sheets-changed drenching, not warmth), unexplained fevers above 38°C, often in odd relapsing patterns, and unintended loss of more than a tenth of body weight over six months. Fatigue beyond the explainable and generalised itching — sometimes severe, sometimes preceding diagnosis by months — are common companions, and a curious minority report pain in affected nodes after alcohol, a peculiar but recognised Hodgkin signature.

The symptom-to-suspicion rule mirrors the platform’s other blood cancers: any node above roughly two centimetres, persisting beyond a few weeks without infective explanation — or any node accompanied by B symptoms — has earned examination and, usually, ultrasound and referral rather than another observational month. In young adults especially, the differential for persistent painless adenopathy is short, and this disease sits near its top.

Itch deserves its odd paragraph: Hodgkin pruritus can be severe, generalised, unresponsive to creams and antihistamines, and can precede any palpable node by months — dermatology clinics know it as one of the classic “investigate beyond the skin” presentations. Unexplained, persistent, whole-body itching in a young adult, particularly with any night sweats, earns bloods and an examination of node regions, not a stronger emollient.

Hodgkin lymphoma begins as a germinal-centre B-lymphocyte that should have died — having botched its antibody-gene rearrangement — but instead survived, shed much of its B-cell identity, and became the Reed-Sternberg clone. What rescues that doomed cell is only partly mapped. The Epstein-Barr virus is the best-established accomplice: its genome sits inside tumour cells in a substantial minority of classical cases (more in mixed cellularity, in childhood and older-adult cases, and in resource-poorer settings), and its proteins can plausibly supply exactly the survival signals the broken cell lacks. Yet EBV infects most of humanity harmlessly, so it is an enabling factor, not an explanation — and EBV-negative Hodgkin needs different, still-unwritten accounts.

Beyond the virus, the established associations are immune context and inheritance. A history of infectious mononucleosis (the symptomatic form of EBV acquisition, typical of delayed exposure in smaller, wealthier families) modestly raises risk; immunosuppression — HIV, organ-transplant drugs, some autoimmune states and their treatments — raises it more sharply; and family clustering is real though modest, with siblings of young patients at elevated risk and twin studies pointing to genuine heritable susceptibility (HLA region variants prominent among the candidates) rather than shared households alone. No occupational, dietary or lifestyle exposure has survived scrutiny as a meaningful cause; smoking shows weak associations in some studies; and the honest sentence for most patients is the one that recurs across this platform’s cancer pages — nothing they did caused this, and nothing they could reasonably have done would have prevented it.

The age pattern itself asks a question science has partly answered: why a cancer of young adults? The leading account ties the young-adult peak to delayed EBV exposure in smaller, more affluent households — infection met in adolescence (often as mononucleosis) rather than harmlessly in infancy — with immune context at the moment of infection shaping risk. It remains an incomplete story, honestly told, and one with no actionable prevention inside it.

The risk profile sketches the epidemiology rather than any individual’s fate. Age draws the famous double peak — late teens to mid-thirties, then again beyond sixty. Sex tilts modestly male overall. A personal history of infectious mononucleosis, and EBV status itself, mark the viral association. Immunodeficiency of any stripe — HIV (where risk is many-fold higher and the disease behaves more aggressively), post-transplant immunosuppression, congenital immune disorders — is the strongest acquired factor. Family history matters at the margins: a sibling or parent with Hodgkin lymphoma raises relative risk while leaving absolute risk small, and no screening of relatives is recommended. Higher childhood socioeconomic status — a proxy for delayed EBV exposure — appears in the nodular-sclerosis young-adult epidemiology; autoimmune disease and its therapies contribute in later-life cases. None of these calls for preventive action beyond the general one: knowing that persistent painless adenopathy in a young adult deserves prompt attention.

Hodgkin lymphoma is staged by the Ann Arbor system (Lugano revision), counting node regions and sides of the diaphragm, suffixed by B where the systemic symptoms are present. Treatment, though, is chosen by risk group — stage plus factors like bulk, node count, age, blood markers — and, mid-treatment, by the interim PET scan that has become the disease’s steering wheel.

Diagnosis rests on tissue, and adequacy matters: because Reed-Sternberg cells are sparse within their inflammatory crowd, a fine-needle aspirate cannot reliably make or exclude the diagnosis — an excisional or generous core biopsy of the most accessible abnormal node is the standard, read by a haematopathologist with immunohistochemistry (the CD30-positive, CD15-positive signature) to fix subtype and rule out mimics. Mediastinal-only disease may need image-guided or surgical biopsy; the principle stays the same — enough architecture for certainty, before any treatment starts.

Staging then belongs to PET-CT, which Hodgkin embraced earlier and more completely than almost any cancer: the whole-body metabolic map defines stage, replaces the staging marrow biopsy in most classical cases (PET finds marrow disease more reliably), fixes the baseline against which response is scored, and — repeated after two cycles as the interim scan, graded on the Deauville 1–5 scale — steers escalation and de-escalation in the response-adapted protocols now standard on both sides of the Atlantic. End-of-treatment PET certifies remission. Between scans, no blood test tracks this lymphoma reliably — there is no Hodgkin “tumour marker” — which surprises patients used to other cancers’ monitoring; examination, symptoms and scheduled imaging carry the follow-up instead, and unexplained new B symptoms between visits are the trigger for bringing imaging forward.

The supporting cast completes the file: blood counts and ESR (a formal risk factor in early-stage grouping), liver and kidney panels, LDH and albumin (prognostic index ingredients in advanced disease), HIV and hepatitis B/C screening (management-changing, and HBV reactivation prophylaxis matters with modern drugs), pregnancy testing, and baseline heart and lung function studies — echocardiogram, pulmonary tests — because the classic regimen’s anthracycline and bleomycin have known cardiopulmonary signatures the team tracks from the start. Fertility counselling belongs here too, before the first cycle: sperm banking, and oocyte or embryo preservation where time allows, are routine offers in a disease that mostly strikes people with reproductive futures.

A note on reading the PET report: “Deauville 1–3” and “complete metabolic response” are the phrases that unlock de-escalation; “Deauville 4–5” prompts escalation or a confirming biopsy — because inflammation, infection and rebound thymus in the young can all light up a scan without a single lymphoma cell present. False positives are common enough that no modern protocol changes treatment on a bright spot alone: certainty is bought with tissue. Knowing this in advance spares patients the worst week of misreading their own results.

The figures that recur through a Hodgkin file, and what they steer.

Untreated, the disease’s complications are progressive: nodes compress airways and vessels (the superior vena cava picture in bulky chest disease), effusions accumulate, marrow and organs are infiltrated, and B-symptom catabolism wastes the body — the reasons cure-intent treatment starts promptly. During treatment, the complications are chemotherapy’s familiar company — count dips with febrile neutropenia as the standing emergency, mucositis, nausea, hair loss — plus two regimen-specific watchpoints: bleomycin’s lung inflammation (cough or breathlessness on treatment is reported early, and the drug is dropped from later cycles in good responders under several modern protocols, or replaced entirely in brentuximab-based regimens) and anthracycline cardiotoxicity, tracked by echocardiography.

It is the decades after cure that give Hodgkin survivorship its particular literature, because the disease’s young, cured population lives long enough to meet late effects. Second cancers lead the list — breast cancer after chest radiotherapy in women treated young (triggering earlier screening under survivorship guidelines), lung, thyroid and others in irradiated fields, and treatment-related leukaemias after certain chemotherapies; cardiovascular disease follows, accelerated by mediastinal radiation and anthracyclines; hypothyroidism is common after neck irradiation; infertility risk varies sharply by regimen (limited with ABVD, substantial with escalated BEACOPP — the fertility conversation belongs before cycle one); and persistent fatigue is the most reported, least visible legacy. Modern protocols exist largely as answers to this list — smaller radiation fields or none, PET-guided de-escalation, bleomycin retirement — and every survivor should hold a written summary of doses received and the surveillance those doses earn.

Pregnancy after cure deserves its clear sentence: fertility permitting, pregnancy after completed treatment is generally safe for mother and child, usually deferred one to two years on standard advice, with no evidence of increased malformation risk from prior chemotherapy or radiotherapy. Where treatment threatened fertility, the preserved options banked before cycle one — this section’s recurring argument — become the road back; fertility clinics and survivor services run that road jointly.

There is no meaningful primary prevention for Hodgkin lymphoma — no vaccine against it, no diet that averts it, no screening test for the general population; EBV is near-universal and the other associations are not modifiable in any practical sense. HIV care is the one real exception: effective antiretroviral therapy lowers the elevated risk that untreated immunodeficiency carries, one more entry in that treatment’s long ledger.

What CAN be protected is the outcome, at three moments. At presentation: acting on the persistent painless node within weeks, because early-stage disease is treated more gently — the node that waits six months may still be cured, but often with more medicine. During treatment: reporting fevers immediately, protecting dose intensity by keeping appointments, banking fertility options before the first cycle, and not smoking (which compounds bleomycin, radiation and cardiovascular late risks measurably). And in survivorship: keeping the tailored surveillance — early breast screening where chest radiotherapy was given young, thyroid checks after neck fields, cardiovascular risk management for life — and carrying the treatment summary that makes any future clinician’s job possible. Relatives need no screening; the familial risk is too small to act on beyond ordinary awareness.

Vaccination around treatment follows the standard immunocompromise logic and is worth listing: influenza and COVID-19 vaccines on schedule (timed between cycles), pneumococcal coverage, and — after any splenic irradiation or splenectomy from older protocols — the full asplenia bundle with its lifetime fever rule. Live vaccines wait for defined recovery milestones. Household members vaccinating normally protects the patient too, a fact families can act on immediately. Units publish their own timing grids for all of this; asking for the printed version at the first visit saves a season of piecemeal questions.

First-line treatment is chemotherapy, dosed to the risk group and steered by the interim PET. Early-stage favourable disease is typically cured with a short course — classically two to four cycles of ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine) — with involved-site radiotherapy either added or, in PET-negative responders on several protocols, omitted to spare late effects; early unfavourable disease earns more cycles and more often keeps the radiotherapy. Advanced disease is treated with six cycles: ABVD with PET-guided bleomycin drop in responders; escalated BEACOPP in the European intensity-first tradition, with PET-guided de-escalation; or — following a major recent trial — brentuximab vedotin or nivolumab combined with AVD, the latter’s results moving checkpoint blockade into first-line conversation for advanced disease. The strategic constant across protocols: treat exactly hard enough, using the PET to earn de-escalation where possible and buy escalation where needed.

Relapsed Hodgkin lymphoma — and refractory disease — has its own established playbook, described fully in the transplant section: salvage chemotherapy to prove chemosensitivity, then high-dose therapy with autologous stem cell rescue — curative for a substantial share. Around and after that spine, the modern drugs have redrawn the map: brentuximab vedotin, the antibody-drug conjugate homing on CD30, serves in salvage, post-transplant maintenance for high-risk cases, and beyond; the checkpoint inhibitors nivolumab and pembrolizumab — exploiting classical Hodgkin’s hard-wired PD-L1 dependence — produce high response rates in relapsed disease and have become standard post-transplant-failure therapy and versatile bridge partners. Allogeneic transplant and CAR-T approaches occupy the far end of the pathway for multiply relapsed disease. Nodular lymphocyte-predominant disease, meanwhile, runs its gentler parallel track — excision or involved-site radiotherapy alone for much early disease, rituximab-containing approaches where more is needed. Older patients deserve their own sentence in any honest treatment section: over-sixties tolerate bleomycin and intensive regimens poorly, trial evidence thins, and geriatric-adapted approaches — brentuximab-based combinations prominent among them — are an active, improving field; age changes the recipe, not the curative intent.

Supportive care threads through: antiemetics and growth-factor support, fertility preservation beforehand, HBV prophylaxis where serology directs, and — in a disease this curable — psychological and survivorship support treated as part of the protocol rather than an afterthought.

The treatment calendar, concretely: ABVD runs as outpatient infusions every two weeks, a “cycle” being two such visits — so early-stage treatment often means eight to twelve chemotherapy days spread across two to four months, with life continuing lopsidedly between them; escalated protocols and radiotherapy add their own appointments. Hair loss is usual and temporary; nausea is largely controlled by modern antiemetics; the fatigue is real and cumulative and lifts over months after the end. Most patients keep studying or working part-time through ABVD; most also report that the second half is harder than the first — an expected pattern, worth knowing rather than discovering.

Transplantation in Hodgkin lymphoma is the relapse chapter’s centrepiece, and the version used first is AUTOLOGOUS — the patient’s own stem cells, not a donor’s. The logic: relapsed Hodgkin can still be killed by chemotherapy at doses that would permanently destroy the marrow, so the marrow is rescued around the cure — stem cells are collected from the patient’s blood after salvage therapy, frozen, and returned after high-dose conditioning (classically BEAM) to regrow blood production within two weeks or so. The decisive predictor is chemosensitivity: patients whose salvage therapy achieves a PET-negative remission carry the best outcomes, which is why the sequence is always salvage first, transplant second, and why a stubborn PET may prompt a different salvage rather than proceeding regardless. Brentuximab maintenance afterwards, for high-risk features, extends progression-free survival per its randomised trial.

Allogeneic transplantation — a donor’s cells and a new immune system — is reserved for later lines: disease returning after autologous transplant, or refractory to it, in patients fit for the undertaking; reduced-intensity conditioning and haploidentical protocols with post-transplant cyclophosphamide have made it more accessible, and the graft-versus-lymphoma effect can hold even multiply relapsed disease, at the cost of graft-versus-host risks the platform’s other blood-cancer pages describe. Its place is being continually renegotiated as checkpoint inhibitors and CAR-T reshape the later lines — a genuinely moving frontier where trial enrolment is mainstream advice.

For international patients the practical notes are these: autologous transplant is a scheduled, self-contained episode — ideal for planned travel — but it must be sequenced correctly with salvage response assessment, so the coordination is of a pathway, not a date; stem cell collection, storage and the transplant itself are best under one roof. The file a centre needs: original diagnostic pathology, all staging and response PETs with dates, every regimen with cycle counts and responses, current organ function, and infection serology. Allogeneic referrals add donor questions — sibling HLA typing where possible before travel. This platform’s standing rule applies unchanged: no page can promise an individual a transplant or its result; what it can do is move a complete file to a team that will answer honestly. The stem cell transplant guide covers the procedure itself.

Hodgkin lymphoma sits among the most curable of all cancers, and the shape of its statistics is worth stating plainly: most patients — across stages — are cured at first treatment, with early-stage favourable disease cured at rates that make de-escalation, not escalation, the modern preoccupation; advanced-stage cure rates, already strong in the PET-adapted era, moved again with the brentuximab- and nivolumab-AVD trials. Relapse, when it comes, usually comes early and still meets a curative pathway: a substantial share of transplanted patients are cured outright, and those who relapse beyond transplant now enter years-long management — sometimes still cure — on checkpoint inhibitors, brentuximab and allogeneic options that simply did not exist a generation ago. Age tempers all of this: older patients tolerate less and their statistics trail the young — one reason geriatric-adapted protocols are an active field.

The consequence of curing the young is the discipline of counting decades, and honest counsel includes it: survivorship carries measurable late risks — second cancers, cardiovascular disease, thyroid failure, fertility effects, fatigue — proportional to the doses and fields received, which is exactly why treatment summaries and tailored surveillance are part of the cure, and why protocols keep shaving toxicity wherever PET permits. Numbers on this page are deliberately framed as patterns rather than percentages: published figures describe cohorts treated under earlier protocols, and this disease’s statistics have a habit of improving before the ink dries. For an individual, the two questions that most shape prognosis are answerable within weeks: the risk group at staging, and the interim PET’s verdict — and both feed a plan whose intent, at every stage of this disease, remains cure.

Survivorship, for this disease, is a decades-long project with a short annual footprint: a treatment summary held by the patient; risk-adapted screening (notably early breast imaging for women irradiated young — commonly starting eight to ten years after treatment); cardiovascular attention that treats a chest-irradiated thirty-year-old’s risk factors the way cardiology treats a fifty-year-old’s; thyroid checks after neck fields; and unembarrassed attention to fatigue and fertility, the two legacies patients report most. Survivor clinics exist precisely to run this programme; where none does, the summary plus this page’s sources equip any primary-care doctor to.